Related Experiment Videos
The potential for hormonal prevention trials
L G Ford1, O W Brawley, J A Perlman
1Detection and Community Oncology Program, National Cancer Institute, Bethesda, Maryland 20892.
Cancer
|November 1, 1994
Summary
Hormonal interventions like tamoxifen for breast cancer and finasteride for prostate cancer are being studied in large trials. These studies aim to determine if these drugs can prevent cancer development and offer insights into cancer risk and prevention strategies.
Area of Science:
- Oncology
- Endocrinology
- Preventive Medicine
Background:
- Breast and prostate cancers share similar causes, risk factors, and treatments.
- Hormonal manipulation is a key area of investigation for cancer prevention.
- Large-scale clinical trials are crucial for evaluating preventive interventions.
Purpose of the Study:
- To evaluate the efficacy of hormonal agents in preventing breast and prostate cancer.
- To assess the impact of tamoxifen on breast cancer development in high-risk women.
- To determine if finasteride reduces prostate cancer incidence in older men.
Main Methods:
- The Breast Cancer Prevention Trial randomizes 16,000 high-risk women to tamoxifen or placebo for 5 years.
- The Prostate Cancer Prevention Trial randomizes 18,000 men over 55 to finasteride or placebo.
- Both trials involve prolonged hormonal intervention to assess cancer incidence.
Main Results:
- The trials are designed to demonstrate if hormonal interventions can significantly decrease cancer risk.
- Data from these trials will provide critical information on cancer etiology and genetics.
- Quantification of the risks and benefits associated with specific preventive strategies will be obtained.
Conclusions:
- Hormonal interventions hold promise for reducing the incidence of breast and prostate cancers.
- These large clinical trials are essential for advancing our understanding of cancer prevention.
- Findings will inform future strategies for cancer risk assessment, screening, and personalized prevention.